GiselaVelezMDMPH, MA

Ophthalmology • Ayer, MA

Retinal Disease, Uveitis

Assistant Professor, Ophthalmology, UMASS Medical School

Join to view full profile

Dr. Velez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Velez's full profile

Already have an account?

Office
190 Groton Rd
Ste 240
Ayer, MA 01432
Phone+1 978-772-4000

Fax+1 978-772-3066

Education & Training

National Institutes of Health Clinical CenterFellowship, Ocular Immunology/Uveitis, 1998 - 2000
MedStar Health/Georgetown-Washington Hospital CenterResidency, Ophthalmology, 1995 - 1998
Georgetown University HospitalInternship, Transitional Year, 1994 - 1995
New York University School of MedicineClass of 1994
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Surgical Retina and Vitreous

Certifications & Licensure

MA State Medical License 2001 - 2026
PR State Medical License 2017 - 2020
VA State Medical License 2000 - 2002
MD State Medical License 1998 - 2001
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Start of enrollment: 2010 Nov 23
Completed
Phase 3
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Start of enrollment: 2014 Oct 01
Completed
Phase 2
Anti-VEGF Treatment for Prevention of PDR/DME Start of enrollment: 2016 Jan 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
Chirag D Jhaveri, Danni Liu, Maureen G Maguire, Adam R Glassman, Ruben A Grigorian
Ophthalmology. 2024-08-01
15 citations
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR R...
Neil M. Bressler, Wesley T. Beaulieu, Susan B. Bressler, Adam R. Glassman, B. Michele Melia
Retina. 2020-06-01
14 citations
SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models.
Gisela Velez, Alexa R. Weingarden, Hetian Lei, Andrius Kazlauskas, Guangping Gao
Investigative Ophthalmology & Visual Science. 2013-02-19

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow